Argent Biopharma Limited Result of AGM

RNS Number : 0229O

Argent Biopharma Limited

28 November 2024

 

 

28 November 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Results of Annual General Meeting

 

Argent BioPharma is pleased to announce the voting results from the Company's Annual General Meeting of Shareholders held today, Thursday, 28 November 2024.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

 

Details of the results can be found in the following URL:

 

https://api.investi.com.au/api/announcements/rgt/568e91c2-8ba.pdf

 

-Ends-

 

Authorised for release by the Company Secretary, for further information please contact:

 

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]

Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]

 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGFEMSUAELSESF